# Neal D. Shore

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/neal-d-shore/

## Facts

| Field | Value |
| --- | --- |
| Citations | 47,064 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 86 |
| i10-index | 386 |
| Last Known Institution | Star Technology and Research (United States) |
| OpenAlex ID | https://openalex.org/A5088518998 |
| ORCID iD | https://orcid.org/0000-0001-5767-0548 |
| Works | 1,308 |

## Researcher papers

- [Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy](https://scholariq.org/papers/increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy/)
- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)
- [Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study](https://scholariq.org/papers/denosumab-versus-zoledronic-acid-for-treatment-of-bone-metastases-in-men-with/)
- [Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/survival-with-olaparib-in-metastatic-castration-resistant-prostate-cancer/)
- [Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-the-report-of-the-advanced/)
- [Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/talazoparib-plus-enzalutamide-in-men-with-first-line-metastatic-castration/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer](https://scholariq.org/papers/improved-outcomes-with-enzalutamide-in-biochemically-recurrent-prostate-cancer/)
- [Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-metastatic-and-or/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

## Researcher university

- [Star Technology and Research (United States)](https://scholariq.org/institutions/star-technology-and-research-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.